Bausch + Lomb Co. (NYSE:BLCO) to Post Q4 2024 Earnings of $0.36 Per Share, HC Wainwright Forecasts

Bausch + Lomb Co. (NYSE:BLCO) – HC Wainwright upped their Q4 2024 EPS estimates for Bausch + Lomb in a note issued to investors on Thursday, May 2nd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of $0.36 per share for the quarter, up from their previous estimate of $0.25. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.66 per share. HC Wainwright also issued estimates for Bausch + Lomb’s FY2025 earnings at $1.03 EPS.

Several other equities research analysts also recently commented on BLCO. Wells Fargo & Company lifted their price objective on shares of Bausch + Lomb from $21.00 to $23.00 and gave the stock an “overweight” rating in a research note on Thursday, February 22nd. Morgan Stanley raised Bausch + Lomb from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $16.00 to $18.00 in a report on Monday. Evercore decreased their target price on Bausch + Lomb from $17.00 to $15.00 and set an “in-line” rating for the company in a report on Thursday, May 2nd. Royal Bank of Canada reduced their price target on shares of Bausch + Lomb from $20.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, April 22nd. Finally, Barclays upped their price objective on shares of Bausch + Lomb from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.45.

Bausch + Lomb Stock Up 3.2 %

BLCO stock opened at $14.90 on Monday. The company has a quick ratio of 1.03, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Bausch + Lomb has a 52 week low of $13.16 and a 52 week high of $21.95. The stock has a market capitalization of $5.24 billion, a PE ratio of -15.52, a price-to-earnings-growth ratio of 1.35 and a beta of 0.47. The firm has a 50 day moving average of $15.71 and a 200 day moving average of $15.57.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). Bausch + Lomb had a negative net margin of 7.81% and a positive return on equity of 3.60%. The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter last year, the business posted $0.10 earnings per share. The company’s quarterly revenue was up 18.0% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Black Swift Group LLC purchased a new position in shares of Bausch + Lomb in the 3rd quarter valued at about $170,000. Jump Financial LLC acquired a new position in shares of Bausch + Lomb during the 3rd quarter worth approximately $255,000. Fore Capital LLC purchased a new position in shares of Bausch + Lomb during the 1st quarter valued at approximately $384,000. Renaissance Capital LLC grew its stake in Bausch + Lomb by 27.3% in the 4th quarter. Renaissance Capital LLC now owns 22,407 shares of the company’s stock valued at $382,000 after acquiring an additional 4,801 shares during the period. Finally, Quadrature Capital Ltd purchased a new stake in Bausch + Lomb in the 3rd quarter worth $466,000. Hedge funds and other institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.